Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kemp JA, Shim MS, Heo CY, Kwon YJ. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv. Drug Delivery Rev. 98, 3–18 (2016).
  Medline CASGoogle Scholar
• 2 Liu Y, Fang J, Kim Y-J, Wong MK, Wang P. Codelivery of doxorubicin and paclitaxel by crosslinked multilamellar liposome enables synergistic antitumor activity. Mol. Pharmaceutics 11(5), 1651–1661 (2014). • Proposes the limitations of cocktail administration and solve these problems by crosslinked multilamellar liposome.
  Medline CASGoogle Scholar
• 3 Liao L, Liu J, Dreaden EC et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J. Am. Chem. Soc. 136(16), 5896–5899 (2014). •• First report about the synthesis of polymer nanoparticles that carry precise molar ratio of three different drugs and open a new door for nanomedicine-based combination therapy.
  Medline CASGoogle Scholar
• 4 Tardi PG, Gallagher RC, Johnstone S et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 1768(3), 678–687 (2007).
  Medline CASGoogle Scholar
• 5 Ma Y, Liu D, Wang D et al. Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer. Mol. Pharmaceutics 11(8), 2623–2630 (2014).
  Medline CASGoogle Scholar
• 6 Miao L, Guo S, Zhang J, Kim WY, Huang L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater. 24(42), 6601–6611 (2014).
  Medline CASGoogle Scholar
• 7 Li M, Tang Z, Lv S et al. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. Biomaterials 35(12), 3851–3864 (2014).
  Medline CASGoogle Scholar
• 8 Zhao C, Shao L, Lu J, Deng X, Tong Y, Wu Y. Hybrid prodrug nanoparticles with tumor penetration and programmed drug activation for enhanced chemoresistant cancer therapy. ACS Appl. Mater. Interfaces 9(22), 18450–18461 (2017).
  Medline CASGoogle Scholar
• 9 Meng H, Wang M, Liu H et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS nano. 9(4), 3540–3557 (2015).
  Medline CASGoogle Scholar
• 10 Zhou S, Sha H, Ke X, Liu B, Wang X, Du X. Combination drug release of smart cyclodextrin-gated mesoporous silica nanovehicles. Chem. Commun. (Cambridge, UK) 51(33), 7203–7206 (2015).
  Medline CASGoogle Scholar
• 11 Fang Y, Zheng G, Yang J et al. Dual-pore mesoporous carbon@silica composite core–shell nanospheres for multidrug delivery. Angew. Chem. Int. Ed. 53(21), 5366–5370 (2014).
  Medline CASGoogle Scholar
• 12 Zhang W, Shen J, Su H et al. Co-delivery of cisplatin prodrug and chlorin e6 by mesoporous silica nanoparticles for chemo-photodynamic combination therapy to combat drug resistance. ACS Appl. Mater. Interfaces 8(21), 13332–13340 (2016).
  Medline CASGoogle Scholar
• 13 Fan L, Jin B, Zhang S, Song C, Li Q. Stimuli-free programmable drug release for combination chemotherapy. Nanoscale 8(25), 12553–12559 (2016).
  Medline CASGoogle Scholar
• 14 Sheu MT, Jhan HJ, Su CY et al. Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. Colloids Surf. B 143, 260–270 (2016).
  Medline CASGoogle Scholar
• 15 Ganguly K, Chaturvedi K, More UA, Nadagouda MN, Aminabhavi TM. Polysaccharide-based micro-/nano-hydrogels for delivering macromolecular therapeutics. J. Control. Rel. 193, 162–173 (2014).
  Medline CASGoogle Scholar
• 16 Zhang B, Wang T, Yang S et al. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J. Control. Rel. 238, 10–21 (2016).
  Medline CASGoogle Scholar
• 17 Han L, Wang T, Wu J, Yin X, Fang H, Zhang N. A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy. Int. J. Nanomed. 11, 6003–6022 (2016). •• Proposes the concept of small molecule based nanodrug.
  Medline CASGoogle Scholar
• 18 Ma W, Cheetham AG, Cui H. Building nanostructures with drugs. Nano. Today 11(1), 13–30 (2016). • Reviews the design, development and advantages of small molecule nanodrug.
  Medline CASGoogle Scholar
• 19 Mallikarjuna Reddy K, Ramesh Babu V, Krishna Rao KSV et al. Temperature sensitive semi-IPN microspheres from sodium alginate and N-isopropylacrylamide for controlled release of 5-fluorouracil. J. Appl. Polym. Sci. 107(5), 2820–2829 (2008).
  Google Scholar
• 20 Chaturvedi K, Kulkarni AR, Aminabhavi TM. Blend microspheres of poly(3-hydroxybutyrate) and cellulose acetate phthalate for colon delivery of 5-fluorouracil. Ind. Eng. Chem. Res. 50(18), 10414–10423 (2011).
  CASGoogle Scholar
• 21 Ganguly K, Aminabhavi TM, Kulkarni AR. Colon targeting of 5-fluorouracil using polyethylene glycol crosslinked chitosan microspheres enteric coated with cellulose acetate phthalate. Ind. Eng. Chem. Res. 50(21), 11797–11807 (2011).
  CASGoogle Scholar
• 22 Thakker SP, Rokhade AP, Abbigerimath SS et al. Inter-polymer complex microspheres of chitosan and cellulose acetate phthalate for oral delivery of 5-fluorouracil. Polym. Bull. 71(8), 2113–2131 (2014).
  CASGoogle Scholar
• 23 Fakih MG, Groman A, Mcmahon J, Wilding G, Muindi JR. A randomized Phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother. Pharmacol. 69(3), 743–751 (2012).
  Medline CASGoogle Scholar
• 24 Wilson PM, El-Khoueiry A, Iqbal S et al. A Phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother. Pharmacol. 65(5), 979–988 (2010). • Fails to determine the MTD of combining vorinostat (SAHA) with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer in a Phase I/II clinical trial.
  Medline CASGoogle Scholar
• 25 South China University of Technology. CN102531964B (2014).
  Google Scholar
• 26 Ren G, Jiang M, Xue P et al. A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy. Nanomedicine (NY, USA) 12(8), 2273–2282 (2016). • The conjugate of hydrophobic docetaxel and D-α-tocopherol succinate (VE) was able to self-assemble into nanoparticle.
  Medline CASGoogle Scholar
• 27 Xu Y, Meng H, Du F et al. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice. Int. J. Pharm. 495(2), 792–797 (2015).
  Medline CASGoogle Scholar
• 28 Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387–6392 (1986).
  Medline CASGoogle Scholar
• 29 Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J. Phys. Chem. 79(2), 926–935 (1983).
  CASGoogle Scholar
• 30 Frisch MJ, Trucks GW, Schlegel HB et al. Gaussian 09, Revision A.1. Gaussian, Inc., Wallingford CT, USA (2009).
  Google Scholar
• 31 Bayly CI, Cieplak P, Cornell W, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 97, 10269–10280 (1993).
  CASGoogle Scholar
• 32 Case DA, Cheatham TE, 3rd, Darden T et al. The amber biomolecular simulation programs. J. Comput. Chem. 26(16), 1668–1688 (2005).
  Medline CASGoogle Scholar
• 33 Gotz AW, Williamson MJ, Xu D, Poole D, Le Grand S, Walker RC. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. generalized born. J. Chem. Theory Comput. 8(5), 1542–1555 (2012).
  Medline CASGoogle Scholar
• 34 Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23(3), 327–341 (1977).
  CASGoogle Scholar
• 35 Zhou RH, Harder E, Xu HF, Berne BJ. Efficient multiple time step method for use with Ewald and particle mesh Ewald for large biomolecular systems. J. Chem. Phys. 115(5), 2348–2358 (2001).
  CASGoogle Scholar
• 36 Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70(2), 440–446 (2010).
  Medline CASGoogle Scholar
• 37 Huang P, Wang D, Su Y et al. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J. Am. Chem. Soc. 136(33), 11748–11756 (2014).
  Medline CASGoogle Scholar
• 38 Plevin MJ, Bryce DL, Boisbouvier J. Direct detection of CH/pi interactions in proteins. Nat. Chem. 2(6), 466–471 (2010).
  Medline CASGoogle Scholar
• 39 Sun D, Ding J, Xiao C, Chen J, Zhuang X, Chen X. Preclinical evaluation of antitumor activity of acid-sensitive PEGylated doxorubicin. ACS Appl. Mater. Interfaces 6(23), 21202–21214 (2014).
  Medline CASGoogle Scholar
• 40 Le VM, Wang JJ, Yuan M et al. An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles. Eur. J. Med. Chem. 92, 882–889 (2015).
  Medline CASGoogle Scholar
• 41 Chaturvedi K, Tripathi SK, Kulkarni AR, Aminabhavi TM. Cytotoxicity and antitumour activity of 5-fluorouracil-loaded polyhydroxybutyrate and cellulose acetate phthalate blend microspheres. J. Microencapsulation 30(4), 356–368 (2013).
  Medline CASGoogle Scholar